Market Size of Neurodegenerative Disease Industry
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 55.12 Billion |
| Market Size (2029) | USD 77.82 Billion |
| CAGR (2024 - 2029) | 7.14 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Neurodegenerative Disease Market Analysis
The Neurodegenerative Disease Market size is estimated at USD 55.12 billion in 2024, and is expected to reach USD 77.82 billion by 2029, growing at a CAGR of 7.14% during the forecast period (2024-2029).
The key growth determinants of the market include the increasing number of neurological disorders, growing awareness globally, and a strong lineup of products for treating neurodegenerative diseases. As the global population grows and people live longer on average, more people are experiencing neurological disorders.
According to data from the National Institute of Environmental Health Sciences, as of June 2022, around 6.2 million Americans had Alzheimer's disease. Furthermore, a study published in the Lancet Journal in March 2024 showed that neurological disorders contribute to 3.4 billion disability-adjusted life-years (DALYs) worldwide. This high burden of neurological disorders is anticipated to increase the demand for treatments and effective methods, driving growth in the neurodegenerative disease market.
The market is set to expand due to increasing attention to developing products for neurodegenerative diseases. For instance, in December 2023, Alpha Cognition reported that the US FDA accepted its New Drug Application for ALPHA-1062, intended for treating Mild-to-Moderate Alzheimer's Disease. ALPHA-1062 is a drug that inhibits acetylcholinesterase, with fewer expected side effects on the stomach.
In March 2024, Prilenia Therapeutics BV shared its plan to submit a Marketing Authorization Application (MAA) for pridopidine to the Medicinal Products for Human Use (CHMP) committee under the European Medicines Agency, seeking approval to treat Huntington's disease (HD). This trend of developing products and obtaining regulatory approvals shows a growing effort to address neurodegenerative diseases, driving market growth.
These factors are expected to contribute to the market's growth during the forecast period. However, strict regulatory requirements and the expiration of patents for treatments of neurodegenerative diseases are significant factors that could hinder market growth.
Neurodegenerative Disease Industry Segmentation
As per the scope of the report, neurodegenerative disease is a broad term used to denote a range of conditions that primarily affect the neurons in the brain. Neurodegenerative diseases are incurable, and neuron degradation leads to neurons' gradual death.
The market is segmented by indication type, drug type, and geography. By indication type, the market is segmented into Parkinson's disease, Alzheimer's Disease, multiple sclerosis, Huntington's disease, and other indication types. By drug type, the market is segmented into N-methyl-D-aspartate receptor antagonists, cholinesterase inhibitors, dopamine agonists, immunomodulatory drugs, and other drug types. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report also covers the market sizes and forecasts in 17 countries across the major regions. For each segment, the market size is provided in terms of value (USD).
| By Indication Type | |
| Parkinson's Disease | |
| Alzheimer's Disease | |
| Multiple Sclerosis | |
| Huntington Disease | |
| Other Indication Types |
| By Drug Type | |
| N-methyl-D-aspartate Receptor Antagonists | |
| Cholinesterase Inhibitors | |
| Dopamine Agonists | |
| Immunomodulatory Drugs | |
| Other Drug Types |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Neurodegenerative Disease Market Size Summary
The neurodegenerative disease market is poised for significant expansion, driven by an increasing prevalence of neurological disorders and heightened global awareness. The market's growth is underpinned by a robust pipeline of products aimed at treating these conditions, as well as ongoing research and development efforts. The aging global population is contributing to a rise in neurological disorders, which in turn is fueling demand for effective treatments. Regulatory approvals and the introduction of novel therapies are further propelling market growth, despite challenges such as stringent regulatory requirements and patent expirations. The Alzheimer's disease segment, in particular, is expected to maintain a substantial market share due to its escalating prevalence and the continuous development of targeted therapies.
North America is anticipated to lead the neurodegenerative disease market, supported by a high incidence of disorders like Alzheimer's and Parkinson's disease, and significant research and development activities. The region's market growth is bolstered by the presence of numerous pharmaceutical companies and advancements in patient care paradigms. Strategic collaborations, mergers, and acquisitions among major players are enhancing competitive positioning and driving innovation. Companies such as AbbVie Inc., Merck & Co. Inc., and Pfizer Inc. are actively involved in developing and launching new products, contributing to the market's semi-consolidated nature. These dynamics, coupled with ongoing clinical trials and regulatory engagements, are expected to sustain the market's upward trajectory over the forecast period.
Neurodegenerative Disease Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rising Prevalence of Neurological Disorders
-
1.2.2 Increasing Public Awareness
-
1.2.3 Strong Product Pipeline for Neurodegenerative Disease Treatment
-
-
1.3 Market Restraints
-
1.3.1 Patent Expiry of Neurodegenerative Disease Treatment Products
-
1.3.2 Stringent Regulatory Guidelines
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD)
-
2.1 By Indication Type
-
2.1.1 Parkinson's Disease
-
2.1.2 Alzheimer's Disease
-
2.1.3 Multiple Sclerosis
-
2.1.4 Huntington Disease
-
2.1.5 Other Indication Types
-
-
2.2 By Drug Type
-
2.2.1 N-methyl-D-aspartate Receptor Antagonists
-
2.2.2 Cholinesterase Inhibitors
-
2.2.3 Dopamine Agonists
-
2.2.4 Immunomodulatory Drugs
-
2.2.5 Other Drug Types
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Neurodegenerative Disease Market Size FAQs
How big is the Neurodegenerative Disease Market?
The Neurodegenerative Disease Market size is expected to reach USD 55.12 billion in 2024 and grow at a CAGR of 7.14% to reach USD 77.82 billion by 2029.
What is the current Neurodegenerative Disease Market size?
In 2024, the Neurodegenerative Disease Market size is expected to reach USD 55.12 billion.
